How Miniaturized Analytics are Transforming Aseptic Bioprocessing Control

An emerging trend in the analytical space for aseptic bioprocessing involves the miniaturization of sample testing and the growing use of microfluidic devices that enable extremely fast detection of microbial contaminants or environmental contamination. Methods that combine filtration, prep, and detection to reduce sample-to-result times are growing in popularity as they can enable real-time or near real-time decision-making. Such methods include systems such as lab-on-chip for rapid screening vs. traditional microbiological culture (1,2).

Traditional analytical methods, particularly time-intensive microbiological culture, create significant bottlenecks that hamper decision-making and delay patient access to therapies (3). The shift toward sample-testing miniaturization and robust integration of rapid microbiological methods (RMMs) allows for real-time or near real-time decision-making, according to Ambili Menon, PhD, senior scientific affairs manager at bioMérieux. Understanding this transition is vital for optimizing workflows, securing compliance, and minimizing financial risk (4).

How does real-time analytical data maximize risk mitigation in aseptic bioprocessing?

The speed of data acquisition is no longer just an operational preference but rather a critical strategic requirement in aseptic bioprocessing, Dr. Menon says. Rapid data acquisition directly supports faster decision-making, which in turn minimizes batch failures and reduces operational downtime, she notes.

“Speed and real-time data in aseptic bioprocessing play a critical strategic role by enabling immediate control over key process parameters, which reduces variability and ensures consistent product quality,” Dr. Menon states.

This capability strengthens compliance and traceability through continuous monitoring and electronic documentation, which are essential for regulatory audits. Furthermore, the early detection of contamination or process deviations helps mitigate risks and protects patient safety. These advancements drive overall operational efficiency by shortening cycle times and supporting lean manufacturing practices, Dr. Menon explains.

She further explains that researchers and operators strategically prioritize analytical bottlenecks using a risk-based approach, which involves focusing on factors most critical to product quality and operational decision-making, particularly those impacting critical quality attributes and critical process parameters. Tools such as failure mode and effects analysis (FMEA), hazard analysis and critical control points (HACCP), and Ishikawa (fishbone) diagrams are used to identify high-risk steps based on severity, occurrence, and detectability (5).

Bottlenecks that delay key decisions, such as sterility or endotoxin testing, are flagged for acceleration, while preference is given to shortening bottlenecks for which faster data yield actionable insights (e.g., real-time microbial monitoring versus offline high-performance liquid chromatography analysis), Dr. Menon notes. The feasibility of integrating technologies like process analytical technology, artificial intelligence/machine learning, and automation also guides this crucial prioritization process, she adds.

What miniaturized systems and RMMs are accelerating biopharma QC?

The technical foundation for this transformation to miniaturized sample testing lies in the growing use of microfluidic devices. These devices enable extremely fast detection of microbial contaminants (e.g., for sterility or bioburden testing) or environmental contamination.

The industry trend is moving toward integrated systems that combine filtration, preparation, and detection to reduce sample-to-result times. These methods include systems like lab-on-chip technology, used for rapid screening (presence/absence) as an alternative to long traditional microbiological culture (6,7). Recent successful adoption of novel analytical technologies in biopharma has focused on enhancing speed, precision, and decentralization of testing, incorporating lab-on-chip platforms for rapid genetic screening and pathogen detection (8).

These RMMs are revolutionizing bioprocessing by significantly reducing testing times for sterility, contamination, and endotoxins, leading to faster and more reliable quality assurance (QA) and quality control (QC) (9).

What non-technical hurdles must biopharma address when adopting integrated RMMs?

However, despite the significant technical and strategic promise of miniaturization and RMMs, their adoption frequently encounters non-technical hurdles, particularly for QC and validation teams that are responsible for transitioning methods, Dr. Menon notes. Significant non-technical challenges include regulatory compliance and validation. New methods must meet rigorous standards, which requires extensive testing to ensure accuracy, reliability, and reproducibility. In addition, integrating these new systems into existing infrastructure—including laboratory information management systems, data platforms, and manufacturing execution systems—is often complex and demands significant cross-functional coordination (10,11).

Cultural resistance also poses a major barrier to implementation, Dr. Menon emphasizes. “Cultural resistance and change management also play a significant role, with operators and quality teams often hesitant to move away from familiar practices like traditional microbiological culture,” she says.

For managers and researchers tasked with presenting results, clear communication regarding the function of rapid testing is paramount, Dr. Menon stresses. “To ensure that non-technical management or production teams correctly interpret rapid analytical results and understand the distinction between speed of screening and assurance of confirmation, researchers and operators should clearly communicate that these tools offer fast preliminary screening rather than definitive confirmation,” she advises.

Framing rapid testing as a proactive risk management tool highlights its role in enabling earlier interventions and preventing costly failures, such as detecting contamination in hours instead of weeks, Dr. Menon continues, noting that it is essential to emphasize that rapid testing supports lean manufacturing and real-time QC.

Where is the greatest strategic opportunity for advanced analytics in biomanufacturing?

When evaluating capital expenditure for integrated, miniaturized systems, companies must strategically weigh these investments against improving the throughput or stability of existing, traditional workflows, Dr. Menon explains. She notes that organizations typically assess financial metrics, such as total cost of ownership, return on investment, and risk mitigation concerning product quality and operational reliability. Thus, investment decisions are influenced by factors, such as the complexity of the product pipeline (e.g., the need for agility to support emerging modalities like messenger RNA and cell therapies) and regulatory trends that encourage the adoption of process analytical technology (PAT) and continuous manufacturing, she states.

Looking ahead, the strategic potential of these analytical advancements is immense, fundamentally transforming key areas of bioprocessing, Dr. Menon says. “Over the next three to five years, the greatest strategic opportunity lies in harnessing advanced analytical technologies—such as microfluidics and RMMs—to fundamentally reshape QA,” she says.

Importantly, these innovations enable proactive process control, faster decision-making, and stronger regulatory compliance through real-time data and early detection capabilities, which represents a paradigm shift for QA—moving from a reactive model to a proactive one. This shift allows for early detection of deviations and immediate corrective actions, Dr. Menon emphasizes. She further explains that the adoption of RMMs aligns strongly with regulatory frameworks such as quality by design and PAT, supporting continuous process verification.

While QA benefits most directly from these analytical advancements in aseptic bioprocessing, the strategic impact extends across the entire value chain, Dr. Menon adds. Faster QA processes accelerate product release, which enhances supply chain velocity, reduces inventory holding costs, and supports lean inventory models. Additionally, rapid methods facilitate agile manufacturing environments, supporting single-use and continuous manufacturing by providing real-time analytics essential for controlling dynamic processes, she explains.

For analytical and manufacturing professionals, mastering these miniaturized and integrated systems represents the critical path toward robust, compliant, and agile bioprocessing operations (12).

References

1. Zhang, J.; Fu, Y.; Fong, C. Y.; et al. Advancements in Microfluidic Technology for Rapid Bacterial Detection and Inflammation-Driven Diseases. Lab Chip 2025, 25, 3348–3373. DOI: 10.1039/D4LC00795F
2. Pinto, I. F.; Abeille, F.; Giehring, S.; et al. PAT-on-a-Chip: Miniaturization of Analytical Assays Towards Data-Driven Bioprocess Development and Optimization. Biosens. Bioelectron. 2025, 286, 117625. DOI: 10.1016/j.bios.2025.117625
3. Halstead, F. D.; Pinjuh, G.; Antonacci, G.; Proudlove, N. Reducing Laboratory Delays in Blood Culture Pathogen Identification: A Quality Improvement Project. BMJ Open Qual. 2025, 14 (1), e003153. DOI: 10.1136/bmjoq-2024-003153
4. Chan, Z. X.; Chelvam, S. P.; Sin, W. X.; et al. Automated, Aseptic Sampling with Small-Volume Capacity from Microbioreactors for Cell Therapy Process Analysis. Front. Bioeng. Biotechnol. 2025, 13, 1612648. DOI: 10.3389/fbioe.2025.1612648
5. Arvanitoyannis, I. S.; Varzakas, T. H. Application of Failure Mode and Effect Analysis (FMEA), Cause and Effect Analysis and Pareto Diagram in Conjunction with HACCP to a Potato Chips Manufacturing Plant. Int. J. Food Sci. Technol. 2007, 42, 1424–1442. DOI: 10.1111/j.1365-2621.2006.01361.x
6. Zhu, H.; Fohlerová, Z.; Pekárek, J.; et al. Recent Advances in Lab-on-a-Chip Technologies for Viral Diagnosis. Biosens. Bioelectron. 2020, 153, 112041. DOI: 10.1016/j.bios.2020.112041
7. Jagannath, A.; Cong, H.; Hassan, J.; et al. Pathogen Detection on Microfluidic Platforms: Recent Advances, Challenges, and Prospects. Biosens. Bioelectron. 2022, 10, 100134. DOI: 10.1016/j.biosx.2022.100134
8. Cui, P.; Wang, S. Application of Microfluidic Chip Technology in Pharmaceutical Analysis: A Review. J. Pharm. Anal. 2019, 9 (4), 238–247. DOI: 10.1016/j.jpha.2018.12.001
9. Ramos, I.; Najera, M.; Schaefer, G. Integration of Rapid Bioburden Testing into Production Quality Management Systems and Process Control. Biotechnol. Prog. March 7, 2024. DOI: 10.1002/btpr.3431
10. Peris-Vicente, J.; Carda-Broch, S.; Esteve-Romero, J. Validation of Rapid Microbiological Methods. J. Lab. Autom. 2015, 20 (3), 259–264. DOI: 10.1177/2211068214554612
11. Lin, N. J.; Servetas, S. L.; Chowdhury, N. N.; et al. Report from the 2022 NIST Rapid Microbial Testing Methods (RMTM) Workshop. NIST Special Publication: NIST SP 1292. August 2023. DOI: 10.6028/NIST.SP.1292
12. Silva, T. C.; Eppink, M.; Ottens, M. Automation and Miniaturization: Enabling Tools for Fast, High-Throughput Process Development in Integrated Continuous Biomanufacturing. J. Chem. Technol. Biotechnol. May 6, 2021. DOI: 10.1002/jctb.6792